Efficiency of Recombinant Bacille Calmette-Guerin in Inducing Humoral and Cell Mediated Immunities against Human Immunodeficiency Virus Type 1 Third Variable Domain in Immunized Mice.
10.3349/ymj.2011.52.1.173
- Author:
Young Jae KIM
1
Author Information
1. Department of Laboratory Medicine, Sungkyunkwan University School of Medicine, Masan Samsung Hospital, Masan, Korea. kyj7514@unitel.co.kr
- Publication Type:Original Article
- Keywords:
HIV-1 vaccine;
V3 domain;
recombinant BCG;
immunized animal
- MeSH:
AIDS Vaccines/genetics/*immunology;
Animals;
BCG Vaccine/genetics/*immunology;
Female;
Guinea Pigs;
HIV-1/*immunology;
Humans;
Immunity, Cellular/genetics/*immunology;
Immunity, Humoral/genetics/*immunology;
Mice;
Mice, Inbred BALB C;
env Gene Products, Human Immunodeficiency Virus/genetics/*immunology
- From:Yonsei Medical Journal
2011;52(1):173-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The third variable (V3) loop of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein has been intensively studied for AIDS vaccine development. Bacille Calmette-Guerin (BCG) is widely used to immunize against tuberculosis and has many advantages as a vaccine vehicle, such as low toxicity, adjuvant potential, low cost, and long-lasting immune-inducing capacity. This work was initiated to investigate the immunogenicity of recombinant BCG (rBCG-mV3) designed to express trimeric HIV-1 V3 loop (mV3) in rBCG-mV3-immunized animals. MATERIALS AND METHODS: HIV-1 V3-concatamer was cloned into pMV261, a BCG-expression vector, and then rBCG-mV3 was constructed by introducing the recombinant plasmid (pMV-V3). The recombinant BCG was examined with regard to its expression of V3-concatamer and the genetic stability in vivo and in vitro. The immune responses induced by recombinant BCG were tested in immunized mice and guinea pigs. RESULTS: The rBCG-mV3 expressed detectable amounts of V3-concatamer when induced by single heat-shock. The recombinant BCG was genetically stable and maintained the introduced mV3 gene for several weeks. V3-specific antibodies were clearly detected 6 weeks after inoculation. The antibody titer rapidly increased after immunization up to 10 weeks, and then maintained for over 4 weeks. IgG2a was prevalent in the V3-specific antiserum. The recombinant BCG was also effective in inducing delayed-type hypersensitivity responses in the immunized guinea pigs. rBCG-immunized mice retained substantial amounts of V3-specific T cells in the spleen, even 5 months after the first immunization. CONCLUSION: Recombinant BCG-mV3 is very efficient in inducing humoral and long-lasting cell-mediated immunity against HIV-1 V3 in the immunized animals.
